AR-R17779
From Wikipedia, the free encyclopedia
 |
|
| Names | |
|---|---|
| IUPAC name
(2S)-2′H-spiro[4-azabicyclo[2.2.2]octane-2,5'-[1,3]oxazolidin]-2'-one
|
|
| Identifiers | |
178419-47-1  |
|
| 3D model (Jmol) | Interactive image |
| ChEBI | CHEBI:CHEBI:420311 |
| ChEMBL | ChEMBL193016  |
| ChemSpider | 4470515 |
| PubChem | 5310971 |
|
|
|
|
| Properties | |
| C9H14N2O2 | |
| Molar mass | 182.22 g·mol−1 |
|
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
|
|
 verify (what is ?) |
|
| Infobox references | |
AR-R17779 is a drug that acts as a potent and selective full agonist for the α7 subtype of neural nicotinic acetylcholine receptors.[1][2] It has nootropic effects in animal studies,[3][4] but its effects do not substitute for those of nicotine.[5] It has also recently been studied as a potential novel treatment for arthritis.[6]
References[edit]
- ^ Mullen, G.; Napier, A.; Balestra, M.; Decory, T.; Hale, G.; Macor, J.; Mack, R.; Loch, J.; Wu, E.; Kover, A.; Verhoest, P.; Sampognaro, A.; Phillips, E.; Zhu, Y.; Murray, R.; Griffith, R.; Blosser, J.; Gurley, D.; Machulskis, A.; Zongrone, J.; Rosen, A.; Gordon, J. (2000). "(-)-Spiro1-azabicyclo2.2.2octane-3,5'-oxazolidin-2'-one, a conformationally restricted analogue of acetylcholine, is a highly selective full agonist at the alpha 7 nicotinic acetylcholine receptor". Journal of Medicinal Chemistry. 43 (22): 4045–4050. doi:10.1021/jm000249r. PMID 11063601.
- ^ Macor, J. .; Mullen, G. .; Verhoest, P. .; Sampognaro, A. .; Shepardson, B. .; Mack, R. . (2004). "A chiral synthesis of (-)-spiro1-azabicyclo2.2.2octane-3,5'- oxazolidin-2'-one: a conformationally restricted analogue of acetylcholine that is a potent and selective alpha7 nicotinic receptor agonist". The Journal of Organic Chemistry. 69 (19): 6493–6495. doi:10.1021/jo049404q. PMID 15357617.
- ^ Levin, E. D.; Bettegowda, C.; Blosser, J.; Gordon, J. (1999). "AR-R17779, and alpha7 nicotinic agonist, improves learning and memory in rats". Behavioural Pharmacology. 10 (6–7): 675–680. doi:10.1097/00008877-199911000-00014. PMID 10780509.
- ^ Van Kampen, M.; Selbach, K.; Schneider, R.; Schiegel, E.; Boess, F.; Schreiber, R. (2004). "AR-R 17779 improves social recognition in rats by activation of nicotinic alpha7 receptors". Psychopharmacology. 172 (4): 375–383. doi:10.1007/s00213-003-1668-7. PMID 14727003.
- ^ Grottick, A. J.; Trube, G.; Corrigall, W. A.; Huwyler, J.; Malherbe, P.; Wyler, R.; Higgins, G. A. (2000). "Evidence that nicotinic alpha(7) receptors are not involved in the hyperlocomotor and rewarding effects of nicotine". The Journal of Pharmacology and Experimental Therapeutics. 294 (3): 1112–1119. PMID 10945867.
- ^ Van Maanen, M.; Lebre, M.; Van Der Poll, T.; Larosa, G.; Elbaum, D.; Vervoordeldonk, M.; Tak, P. (2009). "Stimulation of nicotinic acetylcholine receptors attenuates collagen-induced arthritis in mice". Arthritis and rheumatism. 60 (1): 114–122. doi:10.1002/art.24177. PMID 19116908.
 |
This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it. |
